Edward Dow
Impact in
- Hematology top 10%
- Multiple Myeloma Research and Treatments
- Platelet Disorders and Treatments
Papers in
-
- Multiple Myeloma Research and Treatments 5
- Acute Myeloid Leukemia Research 2
- Chronic Myeloid Leukemia Treatments 1
-
- Protein Degradation and Inhibitors 3
- Phytochemical compounds biological activities 2
- Co-authors
- Jacob J. Lokich (2 shared papers)Peter A. Kouides (1 shared paper)Murray M. Bern (2 shared papers)Flora Peyvandi (1 shared paper)Erik Berntorp (1 shared paper)Peter L. Turecek (1 shared paper)Liviu Niculescu (5 shared papers)Helgi van de Velde (3 shared papers)
- Journals
- Blood (5 papers)Clinical Cancer Research (2 papers)Journal of Clinical Oncology (2 papers)Cancer (2 papers)The Oncologist (1 paper)
- Partner nations
- United StatesBelgiumJapan
In The Last Decade
Edward Dow
15 papers receiving 283 citations
Peers
Comparison fields: 5 of 45
- Hematology 95
- Oncology 63
- Surgery 83
- Pulmonary and Respiratory Medicine 56
- Genetics 17
Countries citing papers authored by Edward Dow
This map shows the geographic impact of Edward Dow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward Dow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward Dow more than expected).
Fields of papers citing papers by Edward Dow
This network shows the impact of papers produced by Edward Dow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward Dow. The network helps show where Edward Dow may publish in the future.
Co-authors
The 25 scholars most cited alongside Edward Dow, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2004 | 76 | |
| 2 | 2015 | 63 | |
| 3 | 2015 | 51 | |
| 4 | 2019 | 38 | |
| 5 | 1999 | 35 | |
| 6 | 1999 | 13 | |
| 7 | 2013 | 7 | |
| 8 | 2014 | 2 | |
| 9 | 2013 | 2 | |
| 10 | 2022 | 2 | |
| 11 | 2021 | 2 | |
| 12 | 2023 | 2 | |
| 13 | 2018 | 2 | |
| 14 | 2015 | 1 | |
| 15 | 2022 | 1 |
About Edward Dow
Edward Dow is a scholar working on Hematology, Molecular Biology, Pathology and Forensic Medicine, Oncology and Cancer Research, having authored 15 papers that have together received 297 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (5 papers), Protein Degradation and Inhibitors (3 papers), Acute Myeloid Leukemia Research (2 papers), Lymphoma Diagnosis and Treatment (2 papers), Phytochemical compounds biological activities (2 papers), HIV/AIDS drug development and treatment (2 papers), Chronic Myeloid Leukemia Treatments (1 paper) and Sarcoma Diagnosis and Treatment (1 paper). The work is most often cited by research in Hematology (95 citations), Oncology (63 citations), Surgery (83 citations), Pulmonary and Respiratory Medicine (56 citations) and Genetics (17 citations). Edward Dow has collaborated with scholars based in United States, Belgium and Japan. Frequent co-authors include Jacob J. Lokich, Peter A. Kouides, Murray M. Bern, Flora Peyvandi, Erik Berntorp, Peter L. Turecek, Liviu Niculescu, Helgi van de Velde, Hongliang Shi and Paul G. Richardson. Their work appears in journals such as Blood, Clinical Cancer Research, Journal of Clinical Oncology, Cancer and The Oncologist.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.